en · de · es · pt
analytical-notes.peptides4088.com › News › Background And Development History — Evidence Review

Background And Development History — Evidence Review

By Editorial Desk · published 2026-01-21 · last reviewed 2026-02-21 · News

The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-02-21. Anything still debated is marked as such rather than presented as settled.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Regulation and Detection Context

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Background And Research Context

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Related pages on this site

Background and Molecular Identity

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Identity and Molecular Context

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Further detail

=== Flower press === This floral preservation has its roots in Victorian times, but has also been brought into the current list of Floral Preservation because of new techniques of pressing, vacuum sealing and color enhancing. This method uses a "flower press" that sandwiches the flower between two rigid layers, often lined with a breathable/adsorbent fabric to allow moisture to leave the flower, then applies a small amount of pressure to the flower, allowing it to keep its shape while it dries. The art is then framed in a flat shadow box style frame, to hang on the wall. Vacuum sealing the art is recommended and the use of Museum Quality glass with a UV Factor of 97% to ensure the colors last.

During Operation Moduler, Cuban combat troops had remained well north of the Lomba River and declined to participate in the fighting, per Castro's instructions. In Luanda, President dos Santos summoned General Gusev and the senior Cuban general officer, Gustavo Fleitas Ramirez, for an urgent conference to discuss the worsening military situation and the failure of Operation Saluting October. Ramirez reminded dos Santos that Cuba had been opposed to the offensive from the beginning. Gusev lamented in his memoirs that "I informed [chief of the Soviet general staff] Akhromeyev about the result of the operation, but the most difficult task, in moral terms, was to inform the president of Angola, whom I had assured that the operation would succeed and that Savimbi would be crushed". On 25 November 1987, United Nations Security Council Resolution 602 was passed, condemning Operation Moduler as an illegal violation of Angolan sovereignty. The resolution expressed dismay at the continued presence of SADF troops in Angola and called for their unconditional withdrawal. South African foreign minister Pik Botha flatly dismissed the resolution out of hand, citing the unaddressed issue of Cuban linkage. He promised that the SADF would depart Angola once FAPLA's Cuban and Soviet advisers had likewise been withdrawn, or when their presence no longer threatened South African interests.

nicking enzyme Also nicking endonuclease and nickase. Any of a class of endonuclease enzymes capable of generating a single-stranded break in a double-stranded DNA molecule, i.e. a nick, either at random or at a specific recognition sequence, by breaking a phosphodiester bond linking adjacent nucleotides.

=== Biosynthesis and metabolism === Polyphenols incorporate smaller parts and building blocks from simpler natural phenols, which originate from the phenylpropanoid pathway for the phenolic acids or the shikimic acid pathway for gallotannins and analogs. Flavonoids and caffeic acid derivatives are biosynthesized from phenylalanine and malonyl-CoA. Complex gallotannins develop through the in vitro oxidation of 1,2,3,4,6-pentagalloylglucose or dimerization processes resulting in hydrolyzable tannins. For anthocyanidins, precursors of the condensed tannin biosynthesis, dihydroflavonol reductase and leucoanthocyanidin reductase (LAR) are crucial enzymes with subsequent addition of catechin and epicatechin moieties for larger, non-hydrolyzable tannins. The glycosylated form develops from glucosyltransferase activity and increases the solubility of polyphenols. Polyphenol oxidase (PPO) is an enzyme that catalyses the oxidation of o-diphenols to produce o-quinones. It is the rapid polymerisation of o-quinones to produce black, brown or red polyphenolic pigments that causes fruit browning. In insects, PPO is involved in cuticle hardening.

== Applications == Scientific techniques, such as immunostaining, depend on chemical specificity. Immunostaining utilizes the chemical specificity of antibodies in order to detect a protein of interest at the cellular level. Another technique that relies on chemical specificity is Western blotting, which is utilized to detect a certain protein of interest in a tissue. This technique involves gel electrophoresis followed by transferring of the sample onto a membrane which is stained by antibodies. Antibodies are specific to the target protein of interest, and will contain a fluorescent tag signaling the presence of the researcher's protein of interest.

Sources: en.wikipedia.org

Supporting material

== Surface energy determination == The main application of IGC is to measure the surface energy of solids (fibers, particulates, and films). Surface energy is defined as the amount of energy required to create a unit area of a solid surface; analogous to surface tension of a liquid. Also, the surface energy can be defined as the excess energy at the surface of a material compared to the bulk. The surface energy (γ) is directly related to the thermodynamic work of adhesion (Wadh) between two materials as given by the following equation:

==== Siberia ==== In 1993, a team of Russian archaeologists led by Dr. Natalia Polosmak discovered the Siberian Ice Maiden, a Scytho-Siberian woman, on the Ukok Plateau in the Altai Mountains near the Mongolian border. The mummy was naturally frozen due to the severe climatic conditions of the Siberian steppe. Also known as Princess Ukok, the mummy was dressed in finely detailed clothing and wore an elaborate headdress and jewelry. Alongside her body were buried six decorated horses and a symbolic meal for her last journey. Her left arm and hand were tattooed with animal style figures, including a highly stylized deer. The Ice Maiden has been a source of some recent controversy. The mummy's skin has suffered some slight decay, and the tattoos have faded since the excavation. Some residents of the Altai Republic, formed after the breakup of the Soviet Union, have requested the return of the Ice Maiden, who is currently stored in Novosibirsk in Siberia. Another Siberian mummy, a man, was discovered much earlier in 1929. His skin was also marked with tattoos of two monsters resembling griffins, which decorated his chest, and three partially obliterated images which seem to represent two deer and a mountain goat on his left arm.

== History == In 1921, Joslin reported the association of diabetes with hypertension and hyperuricaemia. In 1923, Kylin expanded on this triad. In 1947, Vague observed that upper-body obesity predisposed to diabetes, atherosclerosis, gout and calculi. The term metabolic syndrome began appearing in the late 1950s. In 1967, Avogaro, Crepaldi and coworkers described moderately obese people with diabetes, hypercholesterolemia, and marked hypertriglyceridemia that improved on hypocaloric, low-carbohydrate diets. In 1977, Hans Haller used the term for associations of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, and hepatic steatosis. The same year, Singer used it for associations of obesity, gout, diabetes, and hypertension with hyperlipoproteinemia. In 1977–1978, Gerald B. Phillips proposed a "constellation of abnormalities" (glucose intolerance, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, hypertension) and hypothesised sex hormones as a linking factor. The first comprehensive definition of the metabolic syndrome was given in 1981 by the German researchers Markolf Hanefeld and Wolfgang Leonhardt, Dresden, who defined it as a cluster of obesity, hyper- and dyslipoproteinemia, type 2 diabetes, gout, and hypertension, associated with an increased incidence of atherosclerotic vascular disease, fatty liver disease, and gallstones. In 1988, Gerald M. Reaven's Banting lecture proposed insulin resistance as the underlying factor and coined syndrome X.

This is one reason why extreme intakes of any one single micronutrient are not advised. Individuals with chronic digestive problems may be unable to absorb sufficient amounts of copper, even though the foods they eat are copper-rich. Several copper transporters have been identified that can move copper across cell membranes. Other intestinal copper transporters may exist. Intestinal copper uptake may be catalyzed by Ctr1. Ctr1 is expressed in all cell types so far investigated, including enterocytes, and it catalyzes the transport of Cu+1 across the cell membrane. Excess copper (as well as other heavy metal ions like zinc or cadmium) may be bound by metallothionein and sequestered within intracellular vesicles of enterocytes (i.e., predominant cells in the small intestinal mucosa).

The Houthis stepped up their pressure on Hadi's weakened government, seizing the presidential palace and strategic military installations in Sanaa and shelling the president's private residence on 20 January. The following day, they took control of Hadi's home, stationing armed guards outside to keep him under virtual house arrest. Hadi, Prime Minister Khaled Bahah, and the cabinet resigned the following day, saying they could not continue to work under the conditions the Houthis had imposed. The rebel group welcomed Hadi's resignation, but continued to keep him under house arrest. The news prompted four southern governorates to announce they would disregard all orders from Sanaa. The House of Representatives was to meet on 25 January to discuss whether to accept or reject Hadi's resignation under the Yemeni constitution, but the session was cancelled after the Houthis took control of the parliament building. The United Nations stepped in to attempt a negotiated resolution to what many in Yemen regarded as a Houthi coup. UN negotiations were fruitless, and a Houthi ultimatum to Yemen's political factions to find a solution was not met. On 6 February, the Houthis declared themselves in total control of the Yemeni government, dissolving parliament and installing a Revolutionary Committee led by Mohammed Ali al-Houthi to lead the state in an interim capacity. The announcement sparked protests in Sanaa and other cities, especially in the south.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

Is AOD-9604 banned in sport?

Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.

Network